<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D/A
Amendment No. 2
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
Tutogen Medical, Inc.
-------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, Par Value $0.01 Per Share
-------------------------------------------------------------------------------
(Title of Class of Securities)
90110710
-------------------------------------------------------------------------------
(CUSIP Number)
David S. Wise, Esq.
Sulzer Medica USA Inc.
3 East Greenway Plaza, Suite 1600
Houston, Texas 77046
Telephone: (713) 561-6365
-------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 20, 2000
-------------------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of (SS) 240.13d-1(e), (SS) 240.13d-1(f) or (SS) 240.13d-1(g),
check the following box. [_]
<PAGE>
SCHEDULE 13D
----------------------- ---------------------
CUSIP NO. 90110710 PAGE 2 OF 7 PAGES
----------------------- ---------------------
------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Sulzer AG 98-0109623
------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) [_]
(b) [_]
------------------------------------------------------------------------------
SEC USE ONLY
3
------------------------------------------------------------------------------
SOURCE OF FUNDS*
4
WC
------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [_]
5
------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
Switzerland
------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF
0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
OWNED BY 1,344,670 shares of Common Stock
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING
0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
1,344,670 shares of Common Stock
------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
1,344,670 shares of Common Stock
------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
12
[_]
------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
9.0%
------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
CO
------------------------------------------------------------------------------
<PAGE>
SCHEDULE 13D
----------------------- ---------------------
CUSIP NO. 90110710 PAGE 3 OF 7 PAGES
----------------------- ---------------------
------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Sulzer Medica Ltd.
------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) [_]
(b) [_]
------------------------------------------------------------------------------
SEC USE ONLY
3
------------------------------------------------------------------------------
SOURCE OF FUNDS*
4
WC
------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [_]
5
------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
Switzerland
------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF
0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
OWNED BY 1,344,670 shares of Common Stock
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING
0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
1,344,670 shares of Common Stock
------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
1,344,670 shares of Common Stock
------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
12
[_]
------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
9.0%
------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
CO
------------------------------------------------------------------------------
<PAGE>
SCHEDULE 13D
----------------------- ---------------------
CUSIP NO. 90110710 PAGE 4 OF 7 PAGES
----------------------- ---------------------
------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Sulzer Medica USA Holding Co. 13-3169695
------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) [_]
(b) [_]
------------------------------------------------------------------------------
SEC USE ONLY
3
------------------------------------------------------------------------------
SOURCE OF FUNDS*
4
WC
------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [_]
5
------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
Delaware
------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF
0
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
OWNED BY 1,344,670 shares of Common Stock
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING
0
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
1,344,670 shares of Common Stock
------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
1,344,670 shares of Common Stock
------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
12
[_]
------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
9.0%
------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
CO
------------------------------------------------------------------------------
<PAGE>
This Amendment No. 2 (this "Amendment") amends the Statement on Schedule 13D
---------
filed with the Securities and Exchange Commission by Sulzer AG, a corporation
established under the laws of Switzerland, Sulzer Medica Ltd., a corporation
established under the laws of Switzerland, and Sulzer Medica USA Holding Co., a
corporation established under the laws of the State of Delaware (collectively
herein referred to as the "Sulzer Entities") on November 13, 2000 (the "Schedule
--------------- --------
13D") and as amended by Amendment No. 1 on November 21, 2000. This Amendment is
---
filed with respect to the common stock, par value $0.01 (the "Common Stock"), of
------------
Tutogen Medical, Inc., a Florida corporation (the "Issuer") and is filed to
------
reflect information required by Rule 13d-2 under the Securities and Exchange Act
of 1934, as amended, with respect to the Common Stock. The capitalized terms
used in this Amendment and not otherwise defined herein have the meanings
ascribed to such terms in the Schedule 13D.
Item 6. Contracts, Arrangements, Understanding of Relationships with Respect
to Securities of the Issuer
Item 6 is hereby supplemented and amended by the insertion of the
following at the end thereof:
"Pursuant to the Agreement, Sulzer Medica USA Holding Co. entered into
a Loan Agreement dated as of December 20, 2000 (the "Loan Agreement") whereby it
--------------
agreed to make available (or cause to be made available) to the Trust from time
to time, upon the written request of the Liquidating Trustee, such funds in an
aggregate principal amount equal to the exercise price of the Trust's options
and warrants for shares of Common Stock or other equity security of the Issuer.
On December 20, 2000, Sulzer Medica USA lent the Trust $950,000 to exercise
warrants for 700,000 shares of Common Stock. This loan is secured by a pledge
of 700,000 shares of Common Stock to Sulzer Medica USA Holding Co. pursuant to a
Pledge Agreement dated December 20, 2000."
Item 7. Material to be Filed as Exhibits
Item 7 is hereby amended to include the following exhibits, attached
hereto:
Exhibit 99.1 Joint Filing Agreement.
Exhibit 99.3 Loan Agreement dated as of December 20, 2000 between
Sulzer Medica USA Holding Co. and Capital Partners II,
Ltd. Liquidating Trust.
Exhibit 99.4 Pledge Agreement dated December 20, 2000 between Sulzer
Medica USA Holding Co. and Capital Partners II, Ltd.
Liquidating Trust.
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: January 4, 2001
SULZER AG
By: /s/ Roman Beran
---------------------------------------
Name: Roman Beran
Title: Deputy Vice President and General
Counsel, Head of Legal Department
By: /s/ Kurt Haegi
---------------------------------------
Name: Kurt Haegi
Title: Secretary General
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: January 4, 2001
SULZER MEDICA LTD.
By: /s/ Andre P. Buchel
---------------------
Name: Andre P. Buchel
Title: Chief Executive Officer
By: /s/ Vanessa Oelz
------------------
Name: Vanessa Oelz
Title: Secretary General
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: January 4, 2001
SULZER MEDICA USA HOLDING CO.
By: /s/ David S. Wise
-------------------
Name: David S. Wise
Title: Secretary
